Free Trial
NASDAQ:ANAB

AnaptysBio (ANAB) Stock Price, News & Analysis

AnaptysBio logo
$19.99 +0.59 (+3.02%)
As of 01:10 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About AnaptysBio Stock (NASDAQ:ANAB)

Advanced

Key Stats

Today's Range
$19.47
$20.34
50-Day Range
$19.40
$27.00
52-Week Range
$12.21
$39.50
Volume
333,064 shs
Average Volume
736,000 shs
Market Capitalization
$559.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.13
Consensus Rating
Moderate Buy

Company Overview

AnaptysBio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
44th Percentile Overall Score

ANAB MarketRank™: 

AnaptysBio scored higher than 44% of companies evaluated by MarketBeat, and ranked 636th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AnaptysBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.

  • Upside Potential

    AnaptysBio has a consensus price target of $46.13, representing about 128.2% upside from its current price of $20.21.

  • Amount of Analyst Coverage

    AnaptysBio has only been the subject of 3 research reports in the past 90 days.

  • Read more about AnaptysBio's stock forecast and price target.
  • Earnings Growth

    Earnings for AnaptysBio are expected to grow in the coming year, from ($6.08) to ($5.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AnaptysBio is -4.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AnaptysBio is -4.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    AnaptysBio has a P/B Ratio of 8.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about AnaptysBio's valuation and earnings.
  • Percentage of Shares Shorted

    37.91% of the float of AnaptysBio has been sold short.
  • Short Interest Ratio / Days to Cover

    AnaptysBio has a short interest ratio ("days to cover") of 19.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in AnaptysBio has recently increased by 1.04%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    AnaptysBio does not currently pay a dividend.

  • Dividend Growth

    AnaptysBio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    37.91% of the float of AnaptysBio has been sold short.
  • Short Interest Ratio / Days to Cover

    AnaptysBio has a short interest ratio ("days to cover") of 19.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in AnaptysBio has recently increased by 1.04%, indicating that investor sentiment is decreasing.
  • News Sentiment

    AnaptysBio has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for AnaptysBio this week, compared to 5 articles on an average week.
  • Search Interest

    Only 2 people have searched for ANAB on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added AnaptysBio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AnaptysBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $493,202.00 in company stock.

  • Percentage Held by Insiders

    33.50% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about AnaptysBio's insider trading history.
Receive ANAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ANAB Stock News Headlines

Warren Buffett Issues Cryptic Warning on U.S. Dollar
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
AnaptysBio (ANAB) Receives a Buy from Piper Sandler
AnaptysBio (ANAB) Q2 Revenue Jumps 103%
See More Headlines

ANAB Stock Analysis - Frequently Asked Questions

AnaptysBio's stock was trading at $13.24 at the beginning of 2025. Since then, ANAB stock has increased by 52.6% and is now trading at $20.21.

AnaptysBio, Inc. (NASDAQ:ANAB) released its quarterly earnings results on Wednesday, August, 6th. The biotechnology company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.50) by $0.16. The biotechnology company earned $22.26 million during the quarter, compared to analysts' expectations of $11.55 million. AnaptysBio had a negative trailing twelve-month return on equity of 366.98% and a negative net margin of 107.66%.

AnaptysBio's board approved a stock repurchase plan on Monday, March 24th 2025, which allows the company to buy back $75,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 13.1% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's management believes its shares are undervalued.

AnaptysBio (ANAB) raised $60 million in an initial public offering on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

AnaptysBio's top institutional investors include First Light Asset Management LLC (12.64%), Bank of America Corp DE (3.85%), Sofinnova Investments Inc. (3.69%) and 683 Capital Management LLC (1.79%). Insiders that own company stock include Ecor1 Capital, Llc, Daniel Faga, Paul F Lizzul, Eric J Loumeau, Hollings Renton, Dennis Mulroy and Dennis M Fenton.
View institutional ownership trends
.

Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AnaptysBio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Moderna (MRNA) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/06/2025
Today
9/17/2025
Next Earnings (Estimated)
11/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ANAB
CIK
1370053
Fax
N/A
Employees
100
Year Founded
2005

Price Target and Rating

High Price Target
$90.00
Low Price Target
$20.00
Potential Upside/Downside
+133.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.48)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$145.23 million
Net Margins
-107.66%
Pretax Margin
-107.59%
Return on Equity
-366.98%
Return on Assets
-30.58%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.22
Quick Ratio
8.22

Sales & Book Value

Annual Sales
$91.28 million
Price / Sales
6.06
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.33 per share
Price / Book
8.47

Miscellaneous

Outstanding Shares
28,000,000
Free Float
18,618,000
Market Cap
$552.86 million
Optionable
Optionable
Beta
-0.19

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:ANAB) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners